iOrganBio, an innovator in intelligent cell manufacturing that redefines how human cells are engineered and produced at scale for research and therapeutic applications, including FDA-aligned New Approach Methodologies (NAMs), today announced the appointment of Jessica Owens to its Board of Directors. Owens brings over 20 years of company-building and investing experience, including co-founding GRAIL, which raised over $1 billion and formed partnerships with Bristol Myers Squibb, Merck, and Johnson & Johnson, and serving as co-founder and General Partner at Initiate Ventures.
According to iOrganBio, Owens' counsel will be invaluable as the company scales CellForge, expands partnerships, and advances AI-driven cell manufacturing to improve predictability and scalability from model development to cell therapies. CellForge is iOrganBio's AI-powered platform for consistent, scalable, and intelligent manufacturing of cells and organoids for in vitro modeling and cell therapies. By applying engineering precision to biology, CellForge uses AI and automation to guide cell development and make real-time adjustments aligned with defined biological profiles.
At the core of the platform is iOrganBio's functional human CellAtlas, a comprehensive reference built from single-cell and multi-omics data that provides digital blueprints for each cell type. This smart, closed-loop process delivers the accuracy, efficiency, and quality partners need to turn scientific ideas into breakthroughs, accelerating disease modeling, regenerative medicine, and drug development. iOrganBio is based at BioLabs in Chapel Hill, NC. For more information, visit iOrgan.Bio.
Owens' appointment comes as iOrganBio seeks to leverage her deep expertise in building and scaling companies at the intersection of life sciences, health technology, and AI. Her background includes significant experience in venture investing and founding successful ventures, which aligns with iOrganBio's mission to transform human cell production. The company believes her strategic insights will help drive growth and innovation in the rapidly evolving field of AI-driven cell manufacturing.
iOrganBio is focused on improving the predictability and scalability of cell manufacturing, which is critical for developing cell therapies and disease models. With Owens on the board, the company aims to accelerate its partnerships and commercialization efforts. The appointment underscores iOrganBio's commitment to bringing together top talent from the AI and life sciences sectors to advance its technology platform.
